PALO ALTO, Calif., October 01, 2026 – I Peace Inc., a biotech company pioneering induced
pluripotent stem cell (iPS cells) technologies for regenerative medicine and longevity, today
announced that it was selected as one of the awardees for the Top 10 Longevity
Breakthrough Awards at the 2026 Asia-Pacific Healthy Longevity International Summit. The
award was presented for I Peace’s research and development of iPSF, a cell-free product
derived from culture supernatant of iPS cells.
“We are honored to be recognized as one of this year’s Top 10 Longevity Breakthrough
award recipients,” said Dr. Koji Tanabe, Founder and CEO of I Peace, Inc. “This recognition
reflects our team’s commitment to advancing the possibilities of iPS cell technology and
exploring new approaches in the longevity field. We are proud to be included among such
respected innovators and look forward to continuing our efforts to progress iPSC science.”
The Longevity Breakthrough Awards recognizes innovative technologies and research with
the potential to contribute to healthy longevity, based on scientific and medical evidence.
A Cell-Free Technology Focused on Components Derived from iPS Cells
Research and development in regenerative medicine using iPS cells is advancing worldwide,
with clinical trials currently underway across multiple disease areas. Findings from these
studies suggest that the therapeutic effects of iPSC-derived cells may arise not only from the
engraftment and replacement of damaged tissues, but also from various bioactive factors
released by these cells that influence surrounding cells and tissues.
Focusing on these intercellular signaling mechanisms, I Peace has been developing iPSF as a
cell-free technology that utilizes components derived from iPSC-derived cells, rather than
administering the cells themselves.
Researching Potential Applications for Age-Related Cellular and Tissue Changes
iPSF is obtained by isolating and purifying factors produced during the culture supernatant
of iPSC-derived cells. Research conducted to date has observed changes related to
extracellular matrix production and aging-associated biomarkers. I Peace is currently
investigating the underlying mechanisms of action, as well as the safety and potential utility
of iPSF.
In addition, the company is conducting foundational research and exploratory evaluations
into potential applications for various tissues whose function may decline with age, including
skin and hair. Going forward, I Peace plans to carefully assess reproducibility, safety, and
clinical relevance through appropriately designed studies.
Bringing iPS Cell Technology to the Longevity Field
In recent years, research and development in longevity medicine has expanded rapidly
worldwide, with scientists seeking to understand the biological mechanisms of aging and
develop interventions for age-related diseases and functional decline. Within the field of iPS
cell research, interest has also grown beyond tissue regeneration through cell
transplantation to include areas such as cellular rejuvenation, intercellular signaling, and
improvement of the tissue environment, all of which may contribute to extending healthy
lifespan.
I Peace’s business and research activities are centered around three key pillars:
- Manufacturing clinical-grade and research-grade iPS cells for pharmaceutical
companies and research institutions through the GMPeace service. - Providing personal iPS cell banking services to help individuals prepare for future
medical advances through My Peace service. - Conducting longevity-focused research and development based on iPS cell
technologies.
Through this award, I Peace will continue to explore new possibilities for iPS cell technology
while contributing to the extension of healthy lifespan worldwide and the advancement of
the iPS cell manufacturing industry.
Note: iPSF is currently in the research and development stage and is not an approved
pharmaceutical product intended to treat, prevent, or mitigate any specific disease.